Ibrutinib
- PDF / 169,807 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 173 Views
1 S
Haemorrhagic pericardial effusion and cardiac tamponade: case report A 65-year-old woman developed haemorrhagic pericardial effusion and cardiac tamponade during treatment with ibrutinib for chronic lymphatic leukaemia. The woman had been diagnosed with Parkinson’s disease and chronic obstructive pulmonary disease. She had been receiving ibrutinib for chronic lymphatic leukaemia since 2016. Currently, she presented with chest discomfort, worsening shortness of breath and hypoxaemia. Her symptoms progressed for two weeks. Chest CT scan revealed a large pericardial effusion. Echocardiogram showed cardiac tamponade physiology. She underwent an emergency pericardiocentesis with removal of 550 mL of bloody fluid. Pericardial fluid analysis showed protein 5 g/dL, glucose 2 mg/dL, pericardial fluid protein ratio 0.96, LDH 700 µ/L, pericardial fluid to LDH ratio > 0.9 and WBC count of 39696 with 100% neutrophils and RBC count of 156000 [not all units stated]. The woman’s ibrutinib therapy was stopped as the haemorrhagic pericardial effusion and cardiac tamponade secondary to ibrutinib were suspected. After pericardiocentesis, her symptoms resolved. A repeat echocardiogram after five days did not show recurrence of symptoms. Subsequently, she was discharged. However, she died due to the unrelated causes. Patel A, et al. Hemorrhagic pericardial effusion an unreported complication of ibrutinib. American Journal of Respiratory and Critical Care Medicine 199: (plus poster) abstr. 803446303 A3488, No. 9, May 2019. Available from: URL: https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3488 [abstract]
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 18 Jan 2020 No. 1787
Data Loading...
